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Objective: It has been reported that single-nucleotide polymorphism (SNP) in the proximal 
promoter region of apolipoprotein M (apoM) gene may confer the risk in the development of 
type 2 diabetes (T2D) and coronary artery disease (CAD) in the Han Chinese. However, in 
a recent study demonstrated that plasma apoM level did not correlated to the coronary heart 
disease. In the present studies, we investigated the SNP T-778C of apoM gene in CAD patients 
and controls in the Han Chinese population. Moreover we examined whether serum apoM levels 
could be influenced by this promoter mutation.
Material and methods: One hundred twenty-six CAD patients and 118 non-CAD patients were 
subjected in the present study. All patients were confirmed by the angiography. The genotyping 
of polymorphisms T-778C in apoM promoter was determined by real-time polymerase chain 
reaction. Serum apoM levels were semi-quantitatively determined by the dot-blotting analysis.
Results: Distribution of apoM T-778C genotype in non-CAD patients was as following: 84.7% 
were T/T, 15.3% were T/C and 0.0% was C/C. T allele frequencies were 92.4% and C allele, 
7.6%. In the CAD patients, 99 patients (78.6%) had the T/T genotype, 25 patients (19.8%) with 
T/C genotype and 2 patients (1.6%) with C/C genotype. The allele frequency was 88.5% for 
the T allele and 11.5% for the C allele. There was no statistical significant difference of serum 
apoM levels found in these three genotypes.
Conclusions: There was no significant difference in allele or genotype frequencies between 
CAD patients and non-CAD patients. Binary logistic regression analysis with adjustments for 
age, gender, triglycerides, total cholesterol, low-density lipoprotein, high-density lipoprotein, 
apoAI, apoB, and LP(a) indicated that the TC and CC genotypes in SNP T-778C were not 
significantly associated with the development of CAD (odds ratio = 1.510, 95% confidence 
interval: 0.756–3.017; p = 0.243).
Keywords: apolipoprotein M, single-nucleotide polymorphism, coronary artery disease, 
real-time PCR
Introduction
Association of difference genes in relation to the predisposition of cardiovascular 
diseases has been widely examined. Traditional candidate genes of cardiovascular 
disease, such as angiotensin-converting enzyme (ACE) and angiotensinogen (AGT) 
are well known to be correlated to coronary heart disease (CAD), and certain new loci 
that have been recently added to the growing list of the candidate genes, ie, myocyte 
enhancer factor 2 (MEF2A), apolipoprotein M (apoM), phosphodiesterase 4 (PDE4D), 
etc.1 It may conclude that CAD is both multifactorial and polygenic in nature. Atheroma 
formation, the pathological hallmark of CAD, is also an inflammatory process. The 
disorder of lipid profile, especially lower high-density lipoprotein (HDL) cholesterol International Journal of General Medicine 2009:2 178
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and higher low-density lipoprotein (LDL) are important risk 
factors involved in this process.2
ApoM is one of the latest additions to the apolipoprotein 
family, first identified and characterized in 1999.3 The 
apoM gene is located in a highly conserved segment in the 
major histocompatibility complex (MHC) class III locus on 
chromosome 6, and codes for a 22-kDa protein that struc-
turally belongs to the lipocalin superfamily. Human apoM 
cDNA (734 base pairs) contains six exons and encodes 
188-amino acid residue-long protein.4 The 5′-untranslated 
region was 33 nucleotides and the 3′-untranslated region 
120 nucleotides, not including the poly (A) tail. In plasma, 
apoM is mainly confined to HDL, with a small proportion 
present in triglyceride-rich lipoproteins (TGRLP) and LDL. 
In vivo, apoM is selectively expressed in hepatocytes and 
in the tubular epithelium of kidney.5 The anti-atherogenic 
function of HDL is well established. The ability of HDL to 
promote cholesterol efflux from foam cells in atherosclerotic 
lesions is generally regarded as one of the key mechanisms 
behind the anti-atherosclerotic function. Data from apoM-
silencing RNA showed that apoM is critical for the formation 
of HDL, notably pre-β-HDL1. Overexpression of apoM had 
a protective effects against atherosclerosis.6
A variety of candidate genes have been investigated as 
predisposing factors of CAD, including those involved in 
lipid metabolisms.7 It has been reported that single-nucleotide 
polymorphism (SNP T-778C) in the proximal promoter 
region of apoM gene might be associated with the levels of 
plasma cholesterol and fasting plasma glucose, which may 
confer the risk in the development of T2D in Han Chinese.8 
Jiao and collaeagues9 reported that apoM T-778C SNP could 
associate to the CAD and might be a risk factor of CAD, 
whereas Ahnström and colleagues10 recently demonstrated 
contradictorily that plasma apoM was not a predictor of CAD 
events. In order to elucidate whether apoM is a candidate 
gene involving in the pathogenesis of CAD and whether the 
promoter mutation could influence the expression of apoM, in 
the present study, we investigated the genetic polymorphisms 
of T-778C of apoM gene in the CAD patients and control 
subjects in Han Chinese. Moreover we examined the serum 
levels of apoM in the different genotypes.
Materials and methods
subjects
Two hundred forty-four patients who had obtained coronary 
angiography between Jan 2006 and March 2007 were 
subjects of the present study. One hundred twenty-six 
patients were diagnosed as CAD according to the results of 
angiography (a lesion was classed as being significant when 
stenosis was 50%). And 118 patients with normal coronary 
arteries were excluded CAD. All patients were from the third 
affiliated hospital of Suzhou University and were informed 
by written consent.
Genotyping of apoM T-778c 
polymorphisms by using real-time PcR
A 250 µl-sample of peripheral blood was obtained from each 
subject, and DNA was extracted by DNA extract Kit (Shenerg 
Biocolor, Shanghai, China). The SNP ID number and detail 
sequence information of apoM T-778C is publicly available 
(http://www.ncbi.nlm.nih.gov/SNP/rs805296). According to 
the sequence we designed the primers and probes as: forward 
primer: ACTGACACATTCACTCAACATTTATTACTA; 
reverse  primer: AGGGGTTGGTGGTGTTTTGTT; 
sensor  probe:  CTACAAAAGTACAAAAATT-FAM; 
and anchor probe: GTGGTGGCACACGC-TAMRA. All 
specific primers and probes were synthesized and fluores-
cence modified (Invitrogen, Shanghai, China). Taq DNA 
polymerase, 4 × dNTPs, 10 × polymerase chain reaction 
(PCR) buffer, and MgCl2 were purchased from Shenerg 
Biocolor (Shanghai, China). In brief, PCR was performed 
as below: 40 to 80 ng of genomic DNA template, 2.5 µl 
of 10 × PCR buffer, 1.5 mM MgCl2, 0.5 µl of 4 × dNTPs, 
1.25U Taq DNA polymerase, 10 pmol of each primer, and 
2 pmol of each probe in a final reaction volume of 25 µl. 
Thermal cycling was performed in a LightCycler® (Roche, 
Swaziland). The cycling program consisted of 1 min of 
initial denaturation at 95 °C, followed by 40 cycles at 95 °C 
for 0 s (temperature transition rate 20 °C/s), 61 °C for 10 s 
(temperature transition rate 20 °C/s), and 72 °C for 10 s 
(temperature transition rate 20 °C/s). The analytical melting 
program involved melting the PCR products at 95 °C for 
30 s, 30 °C for 4 min, and increased to 80 °C at temperature 
transition rate of 0.1 °C/s, with continuous acquisition of 
fluorescence data.
semi-quantitative determination  
of serum apoM
2 µl of serum was applied to the Hybond-C membrane 
in duplicate (Amersham Biosciences, Piscataway, NJ, 
USA). All samples were applied to the same membrane 
in order to prevent experimental bias. The membrane was 
quenched in the Tris-HCl buffer in presence of 4% Tween 
and 3% BSA overnight at 4 °C, and sequentially incubated 
with primary antibody (dilution, 1:2000 in the Tris-HCl 
buffer) for one hour and then incubated with alkaline International Journal of General Medicine 2009:2 179
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phosphatase (AP) conjugated secondary antibody for one 
hour at room temperature. The development of AP activity 
was performed with a commercial visualization system 
according to the manufacturer’s instructions (Huamei, 
Shanghai, China). The relative amount of apoM were 
analyzed with a Macintosh computer by using the software 
of Quantity One (version 4.2.1, Bio-Rad Laboratories, 
Hercules, CA, USA), and presented as arbitrary units, being 
equivalent to volume density (intensity/mm2).
statistical analysis
Results are expressed as mean ± SD. Comparisons of the 
general characteristics in two groups and serum apoM 
levels between different genotypes were statistically 
evaluated by the unpaired Student’s t-test (Prism software, 
version 4; GraphPad Inc., La Jolla, CA, USA). Significance 
was established at a p value less than 0.05. Binary logistic 
regression analyses were performed by the SPSS statistical 
package (version 10.0, SPSS Inc., Chicago, IL, USA). 
Hardy–Weinberg equilibrium was tested for the T-778C 
polymorphism. Allele frequencies, genotype frequencies, 
odds ratios (ORs) and 95% confidence intervals (CIs) were 
all estimated by Chi-squared analyses.
Results
The general characteristics of non-CAD and CAD patients 
were shown in Table 1. Mean age of non-CAD patients and 
CAD patients were 63.0 ± 10.8 and 62.5 ± 9.4, respectively. 
The non-CAD patients and the CAD patients were matched 
in age and sex (Table 1). It is demonstrated that CAD patients 
had higher triglyceride (TG) levels (2.23 ± 1.57 mmol/L; 
p = 0.001), and lower HDL-C (1.12 ± 0.38 mmol/L; 
p = 0.000) than non-CAD patients (Table 1).
The allele frequencies and genotype distributions of 
T-778C in non-CAD and CAD patients were summarized in 
Table 2. ApoM T-778C genotype distribution in non-CAD 
patients was as follows: 84.7% were homozygous for the 
T allele (T/T), 15.3% were heterozygous (T/C) and 0.0% was 
homozygous for the C allele (C/C). Allele frequencies were 
92.4% for the T allele and 7.6% for the C allele, which was in 
compliance with Hardy–Weinberg equilibrium (p = 0.370). 
In CAD patients, 99 patients (78.6%) had the T/T genotype, 
25 patients (19.8%) had the T/C genotype, and two patients 
(1.6%) had the C/C genotype. The allele frequency was 
88.5% for the T allele and 11.5% for the C allele, which was 
also in the Hardy–Weinberg equilibrium ( p = 0.772). There 
was no statistical significant difference in allele frequencies 
of T and C between CAD and non-CAD patients (OR = 1.575, 
95% CI: 0.850–2.919; p = 0.146) (Table 3).
Furthermore, we compared the plasma lipid levels in 
the non-CAD patients and CAD patients according to the 
genotypes of SNP T-778C, respectively (Table 4). There 
were no statistical significant differences between the 
genotypes in terms of age, gender and plasma lipid levels, 
either in non-CAD patients or in CAD patients. However, 
Mean TG level was higher in CAD patients with TT 
genotype compared to the non-CAD patients (2.29 ± 1.62 vs 
1.61 ± 0.86 mmol/L; p  0.001). The HDL level was lower 
in CAD patients than in non-CAD control group with 
TT (1.12 ± 0.41 vs 1.20 ± 0.30 mmol/L; p  0.001) and 
C allele carriers (1.11 ± 0.27 vs 1.32 ± 0.35 mmol/L; 
p = 0.030) (Table 5). Binary logistic regression analysis 
with adjustments for age, gender, TG, total cholesterol 
(TC), LDL, HDL, apoAI, apoB, and lipoprotein(a) (LP(a)) 
indicated that the TC and CC genotypes in SNP T-778C 
were not significantly associated with CAD (OR = 1.510, 
95% CI: 0.756–3.017; p = 0.243). However, TG levels 
(OR = 1.525, 95% CI: 1.064–2.187; p = 0.022) and HDL 
Table 1 characteristics of cAD and non-cAD patients
  CAD patients 
N = 126
Non-CAD patients 
N = 118
p-value
Male/Female 98/28 88/30 0.557
Age (means ± sD) 62.5 ± 9.4 63.0 ± 10.8 0.619
 TG (mmol/L) 2.23 ± 1.57* 1.71 ± 1.10 0.001
 Tc (mmol/L) 4.50 ± 1.14 4.48 ± 1.01 0.916
LDL-c (mmol/L) 2.22 ± 1.08 2.33 ± 0.91 0.244
hDL-c (mmol/L) 1.12 ± 0.38* 1.22 ± 0.31 0.000
 ApoAI (g/L) 1.19 ± 0.16 1.20 ± 0.14 0.284
 ApoB (g/L) 0.93 ± 0.27 0.88 ± 0.20 0.121
  LP(a) (g/L) 105 ± 73* 104 ± 103 0.034
Notes: Data are means ± sD.  *p  0.05 vs control group.
Abbreviations: cAD, coronary artery disease; LDL-c, low-density lipoprotein 
cholesterol; LP(a), lipoprotein(a); hDL-c, high-density lipoprotein cholesterol; 
sD, standard deviation;   Tc, total cholesterol;   TG, triglycerides.
Table 2 The allele frequencies and genotype distributions 
of   T-778c in non-cAD and cAD patients
Groups Genotypes (n)  Allele 
frequencies (%)
  T/T T/C C/C T C
non-cAD 
patients
100 
(84.7%)
18  
(15.3%)
0  
(0.0%)
92.4 7.6
cAD patients 99  
(78.6%)
25  
(19.8%)
2  
(1.6%)
88.5 11.5
Abbreviation: cAD, coronary artery disease.International Journal of General Medicine 2009:2 180
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levels (OR = 0.308, 95% CI: 0.098–0.969; p = 0.044) were 
significantly associated with CAD. As shown in Figure 1, 
there was no statistical significant difference of serum apoM 
levels found in these three genotypes.
Discussion
HDL is generally regarded as an antiatherogenic component 
in the circulation, mainly ascribed to its role in the “reverse 
cholesterol transport”. In genetically modified mice, apoM 
is critical for the formation of HDL particles, notably in 
the pre-β-HDL.6 Christoffersen and colleagues11 compared 
the properties of human HDL particles that contain apoM 
with those that did not. ApoM+ particles were significantly 
more efficient in promoting the efflux of cholesterol from 
prelabelled THP-1 cells, lending support to the notion that 
one mechanism behind the anti-atherogenic effect of apoM 
reflects a role in the reverse cholesterol transport. The abil-
ity of HDL to promote cholesterol efflux from foam cells in 
atherosclerotic lesions is generally regarded as one of the 
key mechanisms behind its protective function. However, as 
a new potential marker for atherosclerotic diseases in man, 
apoM was still little investigated.
More recently, a potential involvement of apoM 
polymorphisms with certain diseases was of interest. 
Kabbara and colleagues12 excluded that apoM was a 
candidate gene for Alzheimer’s disease in the French popula-
tion. Study of the SNPs located in apoM proximal promoter 
region found that the SNP T-778C conferred the risk of 
development of type 2 diabetes and CAD.8,9 However, a 
population-based nested case-control study showed that 
apoM had no association with coronary heart disease.10
As it is difficult to obtain appropriate control groups 
for the association studies in CAD,13 in our initial study 
we chose participants without any symptoms suggestive of 
CAD as the control group. Data showed that there was no 
significant difference in the allele frequencies of T and C 
between CAD patients and healthy volunteers (OR = 1.019, 
95% CI: 0.659–1.575; p = 0.934. Data not shown). The 
healthy group may have contained some volunteers who 
had potential stenoses of their coronary arteries, but were 
not showing symptoms. Compared to the CAD group, this 
control group was much younger. Perhaps these individuals 
may have certain genes to initiate and develop CAD in the 
future, therefore the younger subjects are not proper controls. 
Furthermore we chose age- and gender-matched patients with 
normal coronary arteries who were excluded from CAD as 
controls. The results confirmed our previous finding that 
there was no association in the allele frequencies of T and C 
between CAD patients and non-CAD patients (OR = 1.575, 
95% CI: 0.850–2.919; p = 0.146). Binary logistic regression 
analyses with adjustments for age, gender, TG, TC, LDL, 
HDL, apoAI, apoB, and LP(a) indicated that the TC and CC 
genotypes in SNP T-778C were not significantly associated 
with CAD (OR = 1.510, 95% CI: 0.756–3.017, p = 0.243).
Given the evidence implicating apoM in the pathogenesis 
of CAD, there are several possible explanations for the lack 
of association observed in the present study. First, it was 
Table 3 Tests for association of cAD patients and non-cAD 
patients
  p value X  2 OR 95% CI
T/c 0.146 2.11 1.575 0.850–2.919
TT/Tc 0.318 1.00 1.403 0.720–2.732
TT/cc 0.157 2.00 5.050 0.239–106.530
TT/(Tc + cc) 0.214 1.54 1.515 0.785–2.926
Abbreviations: CAD, coronary artery disease; CI, confidence interval; OR, odds ratio.
Table 4 characteristics of non-cAD and cAD patients according to the genotypes of snP T-778c (Data are means ± sD)
Non-CAD patients p value CAD patients p value
  TT TC + CC   TT TC + CC  
Age (years) 63.0 ± 10.9 63.5 ± 10.3 0.920 62.6 ± 9.5 62.5 ± 9.4 0.739
 TG (mmol/L) 1.61 ± 0.86 2.24 ± 1.90 0.252 2.29 ± 1.62 2.01 ± 1.39 0.150
 Tc (mmol/L) 4.45 ± 0.91 4.65 ± 1.47 0.428 4.49 ± 1.16 4.54 ± 1.08 0.842
LDL-c (mmol/L) 2.32 ± 0.90 2.44 ± 1.01 0.539 2.17 ± 1.09 2.41 ± 1.04 0.287
hDL-c (mmol/L) 1.20 ± 0.30 1.32 ± 0.35 0.265 1.12 ± 0.41 1.11 ± 0.27 0.658
 ApoAI (g/L) 1.20 ± 0.13 1.23 ± 0.15 0.530 1.19 ± 0.15 1.18 ± 0.19 0.589
 ApoB (g/L) 0.87 ± 0.18 0.90 ± 0.29 0.860 0.93 ± 0.28 0.94 ± 0.24 0.677
  LP(a) (g/L) 105 ± 99 97 ± 123 0.479 108 ± 77 95 ± 53 0.327
Abbreviations: ApoAI, apolipoprotein AI;   ApoB, apolipoprotein B; cAD, coronary artery disease; LDL-c, low-density lipoprotein cholesterol; LP(a), lipoprotein(a); 
hDL-c, high-density lipoprotein cholesterol; sD, standard deviation; snP, single nucleotide polymorphism;   Tc, total cholesterol;   TG, triglycerides.International Journal of General Medicine 2009:2 181
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possible that the lack of any association with CAD could be 
the lack of power of the study to observe a difference in only 
126 patients. Second, this polymorphism may be function-
ally silent. The results of the serum apoM levels between 
different genotype groups suggested the mutant promoter 
might not effect apoM gene expression. In the present study, 
we used semi-quantitative method to estimated serum apoM 
levels, more precise methods are guaranteed to be applied 
in further study. Third, Marenberg and colleagues suggested 
that at younger ages, death from coronary heart disease is 
influenced by genetic factors in both women and men, but 
the genetic effect decreases at older ages and a genetic effect 
may therefore be diluted.14 Thus, perhaps the effect of apoM 
polymorphism in our study was decreased in CAD patients 
because of age factors. Finally, initiation and development 
of CAD are quite complicated; several risk factors might 
influence its process, such as body mass index, smoking 
history, family history, and environmental effects.15 The 
complicated progression of CAD suggested that CAD is a 
multifactorial and multigenetic disease.
Although direct clinical studies of human apoM in 
relation to CAD are still scarce, more and more data indi-
cate that there is a linkage between apoM and risk factors of 
cardiovascular disease such as diabetes and obesity. It is a 
challenge to define the roles of apoM in man, and to elucidate 
its physiopathological role on regulation of HDL metabolism 
and on anti-atherosclerotic processes.
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